



## Saturday, March 11, 2023

### All session times are in Mountain Time

<u>6:30 AM – 7:00 AM</u> Breakfast with the Vendors

#### 7:00 AM - 9:30 AM

## **Alpha Therapy**

The talks will discuss the current status of alpha therapy, including availability and what agents are likely to be approved in the near future

Session Chair: Andreas Kjaer, MD, PhD, DMSc, MBA

Co-Chair: Michael Graham, MD, PhD

## **Session Topics:**

Isotope Availability Now and in the Future - Focus on Alphas

Speaker: Roy Brown, MBA

Targeted alpha therapy in neuroendocrine tumors: results from <sup>212</sup>Pb-DOTAMTATE clinical trials

Speaker: Dr. Ebrahim Delpassand, MD

VMT-alpha-NET - why does it have to be alpha?

Speaker: Frances Johnson, MD

211At - an Ideal Alpha Emitter?
Chair: Andreas Kjaer, MD, PhD

#### 1:00 PM - 3:00 PM

## **Roundtable: General Oncology**

We will discuss the latest papers on FAPI, covering both diagnostic and therapeutic applications. Other topics may be discussed, depending on participant interests.

Lead: Mike Graham, MD, PhD

4:00 PM - 4:25 PM Hal O'Brien Award Talk

## **Scheduled Topic:**

Integration of theranostics into cancer patient management

Speaker: Amir Iravani, MD

4:30 PM – 7:30 PM Prostate Update In this session, we will discuss the role of nuclear medicine in evaluating and treating patients with advanced prostate cancer. We will review the appropriate use criteria for PSMA PET/CTs, the use of radioligand therapy in the clinic, and the future of theranostics. We as well discuss the critical steps in opening a theranostic center.

Session Chair: Bital Savir-Baruch, MD Co-Chair: Michael Graham, MD, PhD

## **Session Topics:**

PSMA PET- Appropriate use criteria and patient selection for radioligand therapy

Speaker: Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, FSNMMI

Therapy of prostate cancer with Lu177-PSMA

Speaker: Tom Hope, MD

Radioligand therapy Beyond Vision and TheraP trials- Review of clinic trials for Prostate cancer

Speaker: Vikas Prasad, MD

How to build and design a Theranostic center

Chair: Bital Savir-Baruch, MD, FACNM

## Sunday, March 12, 2023

## All session times are in Mountain Time

### 6:30 AM - 7:00 AM

**Breakfast with the Vendors** 

## 7:00 AM - 9:30 AM

#### **Cutting Edge Nuclear Cardiology**

This session will outline the contemporary role for cardiac PET and SPECT in disease diagnosis and risk stratification. The speakers will highlight the latest advances in clinical nuclear cardiology which will enable nuclear Cardiology to retain a prominent role in the management of patients with known or suspected coronary artery disease.

Session Chair: Rob Miller Co-Chair: Dan Berman, MD

## **Session Topics:**

Guidelines for Chest Pain Imaging: Where do SPECT and PET fit in?

Speaker: Dennis Calnon, MD, FACC, FASE, MASNC, FSCCT

### **PET Myocardial Perfusion Imaging and Flow:**

Speaker: Krishna K. Patel, MD, MSc

F-18 Flurpiradaz Perfusion Imaging; the Time is Now

Speaker: Dan Berman, MD

F-18 Sodium fluoride; applications in coronary disease

Speaker: David Newby, PhD

**Enhancing SPECT: flows, CAC, quantitation** 

Speaker: Robert Miller

## 1:00 PM - 3:00 PM

**Roundtable: Discussing the Future of Nuclear Cardiology** 

During this interactive session, speakers will discuss the future landscape for nuclear Cardiology. This forward-looking session will provide an overview of emerging applications including potential future directions for cardiac PET, the important role for nuclear Cardiology in infiltrative cardiomyopathies, and novel PET radiotracers with non-coronary applications.

Lead: Rob Miller

Co-Lead: Dan Berman, MD

## **Topics:**

Where to take cardiac PET after CAC and flows

Speaker: Piotr Slomka, PhD

Hybrid imaging in cardiac amyloidosis and sarcoidosis

Speaker: Robert Miller

Emerging novel tracers including GP1, FAPI, and valvular applications of F18

Speaker: David Newby, PhD

### 4:00 PM - 5:40 PM

#### Instrumentation

We will review the latest advances in the nuclear medicine instrumentation, including total body PET, digital and other novel PET designs as well as latest generation of SPECT/CT scanners.

Session Chair: Piotr Slomka, PhD Co-Chair: Ramsey Badawi, PhD

## Scheduled Topics: PhD Whole Body PET

Speaker: Ramsey Badawi, PhD

**Digital PET** 

Speaker: Keisha McCall, PhD

**Latest developments in digital CZT SPECT** 

Speaker: Benjamin Auer, PhD Latest SPECT developments

Speaker: Hans Vija

## 5:40 PM - 6:30 PM

Hal O'Brian Award Talks

### **Scheduled Topics:**

Towards the routine clinical adoption of whole-body and total-body multi-parametric PET using cost-effective imaging technologies

Speaker: Nicolous Karakatsanis, PhD

## **Uncovering Tumor Biology through Molecular Imaging**

Speaker: Patricia Ribeiro Pereira PhD

## 7:00 PM - 9:00 PM

## Sunday Night Dinner & Hal O'Brien Rising Star Award Ceremony

Open to all in-person attendees with meeting registration. Additional tickets available for guests.

#### All session times are in Mountain Time

### 6:30 AM - 7:00 AM

**Breakfast with the Vendors** 

## 7:00 AM - 9:30 AM

## **Policy and Regulatory Updates**

Federal legislative and regulatory activity related to nuclear medicine remains robust, with recent significant developments such as passage of new drug pricing legislation within the Inflation Reduction Act. A number of important regulatory initiatives have been or will be underway within the Nuclear Regulatory Commission. The mid-term elections have result in split control of the Congress. This session will provide updates regarding an overview of ongoing legislative and regulatory changes impacting the nuclear medicine sector.

Session Chair: Ira Goldman, MA

Co-Chair: Cathy Cutler

# Scheduled Topics: SNMMI Update

Speaker: Cathy Cutler

**TBD** 

Speaker: Scott Bartley MD

**FIND Act update** 

Speaker: Ira Goldman, MA

PAMA/AUC Update Speaker: Kathy Flood

**Current NRC nuclear medicine topics including Emerging Medical Technologies** 

Speaker: Christian Einberg

## 1:00 PM - 3:00 PM

Roundtable: Barriers to Access/Equity & Diversity in Clinical Trials/Barriers to a more diverse workforce

We will discuss current Diversity, Equity, and Inclusion activities in nuclear medicine and molecular imaging as well as possible ways to increase diversity in the nuclear medicine community.

Lead: Thomas Ng, MD

### 4:00 PM - 7:30 PM

## **Neuroimaging**

In this session we will discuss the use and role of PET tracers (beta amyloid and tau) in pivotal late stage Alzheimer's Disease (AD) clinical trials, as well as use and development of PET tracers in non-AD neurodegenerative diseases.

Session Chair: Andrew Stephens, MD, PhD

Co-Chair: Maria Ponisio, MD

## **Scheduled Topics:**

Update on AD clinical trials and the role of imaging biomarkers

Speaker: Mike Pontecorvo, PhD

Relationship between tau deposition and the functional network architecture of the brain

Speaker: Nicolai Franzmeier, PhD

Neuroimaging in CTE/TBI

Speaker: Mike Alosco, CTE

Imaging primary tauopathies and movement disorders

Speaker: Andrew Stephens, MD, PhD

New tracers for imaging neuroinflammation and tau

Speaker: Neil Vasdev, PhD

## Tuesday, March 14, 2023

#### All session times are in Mountain Time

6:30 AM - 7:00 AM

**Breakfast with the Vendors** 

### 7:00 AM - 9:30 AM

## Al/machine learning

Latest AI developments applied to nuclear medicine will be presented with examples in nuclear cardiology including the clinical perspective, PET brain imaging, and automated segmentation of oncological images.

Session Chair: Piotr Slomka, PhD Co-Chair: Joyita Dutta, PhD

## **Scheduled Topics:**

AI-Enabled PET Imaging for Alzheimer's Disease

Speaker: Joyita Dutta, PhD

Al-powered nuclear cardiology

Chair: Piotr Slomka, PhD

How AI can help cardiovascular imaging clinicians

Speaker: Rob Miller, MD

Addressing clinical challenges in prostate cancer with an automated AI-based analysis of PSMA prostate

images

Speaker: Sai Duriseti, MD

## 2:30 PM - 3:45 PM

Roundtable: Al

## 4:00 PM - 7:30 PM

**Controversies in Thyroid Cancer Therapy** 

Although we have been treating thyroid cancer with I-131 for 70 years, we still cannot agree on the best way.

Session Chair: Michael Wissmeyer, MD, PhD

Co-Chair: Mike Graham, MD, PhD

## **Scheduled Topics:**

Recombinant human thyrotropin versus thyroid hormone withdrawal in the management of differentiated thyroid cancer: examining the evidence

Speaker: Jennifer Kwak, MD

## **Update on the 2022 Joint SNMMI-EANM Thyroid Cancer Guidelines**

Speaker: Anca Avram, MD

# Radioiodine in differentiated thyroid carcinoma, an ever hot topic

Speaker: Michael Wissmeyer, MD, PhD, slides provided by Michael Kreissl, MD

# The Swiss consensus in low risk thyroid carcinoma

Speaker: Michael Wissmeyer, MD, PhD